Huntington Ingalls Industries Inc vs Nuwellis Inc — how do they compare? Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Huntington Ingalls Industries Inc is far larger — about 4745.5× Nuwellis Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Nuwellis Inc for 26 Days on average.
| HII | NUWE | |
|---|---|---|
Market Cap | $10.44B | $2.20M |
Volume | 440,462 | 121,544 |
Sector | Industrials | Health |
52-Week High | $453.73 | $146.65 |
52-Week Low | $257.05 | $0.68 |
Typical Hold Time | 28 Days | 26 Days |
Enterprise Value | $13.37B | -$1.52M |
Dividend Yield | 2.08% | — |
Signals from Pluang's Aura AI — not financial advice
HII trades at $265.02, up 1.67% today, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $5.27 surpassing expectations. Recent contract wins, including a $5.1 billion aircraft carrier overhaul, bolster revenue visibility from a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.78 and P/S of 0.79.
The outlook is supported by robust defense budgets and contract momentum, but technical weakness and mixed analyst sentiment (40.7% buy, 55.6% hold) suggest near-term caution. Key risks include execution on large projects and defense spending cycles. The consensus price target of $363.67 implies significant upside if operational targets are met.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →